IntelGenx Technologies 10Q 2024 Q1 Quarterly report

IntelGenx Technologies (IGXT) 10-Q2024 Q1 Quarterly report

Content analysis

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to________

Commission File Number 000-31187

INTELGENX TECHNOLOGIES CORP.

(Exact name of small business issuer as specified in its charter)

Delaware	87-0638336
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

6420 Abrams, Ville Saint Laurent, Quebec H4S 1Y2, Canada

(Address of principal executive offices)

(514) 331-7440

(Issuer's telephone number)

(Former Name, former Address, if changed since last report)

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer", "non-accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [ ] (Do not check if a smaller reporting company)		Smaller reporting company [X]

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

Yes [ ] No [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

APPLICABLE TO CORPORATE ISSUERS:

174,658,096 shares of the issuer's common stock, par value $.00001 per share, were issued and outstanding as of May 14, 2024.

IntelGenx Technologies Corp.

Form 10-Q

TABLE OF CONTENTS

IntelGenx Technologies Corp.

Consolidated Financial Statements

March 31, 2024

(Expressed in U.S. Funds)

(Unaudited)

Contents

Consolidated Balance Sheet	2

Consolidated Statement of Shareholders' Deficit	3

Consolidated Statement of Comprehensive Loss	4

Consolidated Statement of Cash Flows	5

Notes to Consolidated Financial Statements	6 - 22

IntelGenx Technologies Corp.

Consolidated Balance Sheet

(Expressed in Thousands of U.S. Dollars ($'000) Except Share and Per Share Data)

(Unaudited)

		March 31, 2024			December 31, 2023
Assets
Current
Cash	$	772		$	2,282
Accounts receivable		618			622
Prepaid expenses		239			223
Investment tax credits receivable		201			168
Security deposits		74			75
Inventory (note 4)		173			71
Total current assets		2,077			3,441
Leasehold improvements and equipment, net (note 5)		3,682			3,958
Security deposits		244			250
Operating lease right-of-use-asset		545			633
Total assets	$	6,548		$	8,282

Liabilities
Current
Accounts payable and accrued liabilities		3,023			2,661
Accrued interest expense (note 9)		1,426			1,249
Current portion of operating lease liability (note 13)		242			248
Current portion of finance lease liability (note 13)		82			90
Deferred revenue		1,009			1,118
Convertible notes (note 7)		2,585			2,557
Term loan (note 8)		500			500
Loan payable (note 9)		7,649			-
Total current liabilities		16,516			8,423

Loan payable (note 9)		670			7,401
Convertible notes (note 7)		4,538			4,438
Operating lease liability (note 13)		170			230
Finance lease liability (note 13)		20			37
Total liabilities		21,914			20,529
Contingencies (note 16)		-			-
Shareholders' deficit
Capital stock, common shares, $0.00001 par value; 580,000,000 shares authorized; 174,658,096 shares issued and outstanding (2023: 174,658,096 common shares) (note 10)		1			1
Additional paid-in capital (note 11)		69,262			68,662
Accumulated deficit		(82,484	)		(78,457	)
Accumulated other comprehensive loss		(2,145	)		(2,453	)
Total shareholders' deficit		(15,366	)		(12,247	)
	$	6,548		$	8,282

See accompanying notes

Approved on Behalf of the Board:

/s/ Bernd J. Melchers Director /s/ Horst G. Zerbe Director

IntelGenx Technologies Corp.

Consolidated Statement of Shareholders' Deficit

Period Ended March 31, 2024

(Expressed in Thousands of U.S. Dollars ($'000) Except Share and Per Share Data)

(Unaudited)

										Accumulated
					Additional					Other			Total
	Capital Stock				Paid-In		Accumulated			Comprehensive			Shareholders'
	Number		Amount		Capital		Deficit			Loss			Deficit

Balance - December 31, 2023	174,658,096	$	1	$	68,662	$	(78,457	)	$	(2,453	)	$	(12,247	)

Other comprehensive income	-		-		-		-			308			308

Issuance of warrants to atai Life Sciences (net of transaction costs of $11) (note 9)	-		-		300		-			-			300

Stock-based compensation (note 11)	-		-		300		-			-			300

Net loss for the period	-		-		-		(4,027	)		-			(4,027	)

Balance - March 31, 2024	174,658,096	$	1	$	69,262	$	(82,484	)	$	(2,145	)	$	(15,366	)

See accompanying notes

IntelGenx Technologies Corp.

Consolidated Statement of Comprehensive Loss

(Expressed in Thousands of U.S. Dollars ($'000) Except Share and Per Share Data)

(Unaudited)

		For the Three-Month Period Ended March 31,
		2024			2023

Revenues (note 12)	$	174		$	162
Total revenues		174			162
Expenses
Research and development expense		789			822
Manufacturing expense		484			472
Selling, general and administrative expense		1,934			1,295
Depreciation of tangible assets		202			192
Total expenses		3,409			2,781
Operating loss		(3,235	)		(2,619	)
Interest income		-			14
Financing and interest expense		(792	)		(319	)
Net financing and interest expense		(792	)		(305	)
Net loss		(4,027	)		(2,924	)
Other comprehensive income
Change in fair value		-			1
Foreign currency translation adjustment		308			3
		308			4
Comprehensive loss	$	(3,719	)	$	(2,920	)

Basic and diluted:
Weighted average number of shares outstanding		174,658,096			174,646,196
Basic and diluted loss per common share (note 15)	$	(0.02	)	$	(0.02	)

See accompanying notes

IntelGenx Technologies Corp.

Consolidated Statement of Cash Flows

(Expressed in thousands of U.S. Dollars ($000's) Except Share and Per Share Data)
(Unaudited)

		For the Three-Month Period
		Ended March 31,
		2024			2023
Funds (used) provided -
Operating activities
Net loss	$	(4,027	)	$	(2,924	)
Depreciation of tangible assets		202			192
Stock-based compensation		300			11
Accretion expense		381			48
DSU expense		244			144
Lease non-cash expense		(2	)		1
		(2,902	)		(2,528	)
Changes in non-cash items related to operations:
Accounts receivable		4			119
Prepaid expenses		(16	)		(75	)
Investment tax credits receivable		(33	)		(37	)
Inventory		(102	)		(8	)
Accounts payable and accrued liabilities		125			267
Accrued interest expense		177			-
Deferred revenues		(109	)		-
Net change in non-cash items related to operations		46			266
Net cash used in operating activities		(2,856	)		(2,262	)
Financing activities
Finance lease payments		(22	)		(9	)
Issuance of convertible loan		1,000			3,000
Transaction costs of convertible loan		(35	)		-
Net proceeds from convertible notes		-			697
Transaction costs of convertible notes		-			(40	)
Net cash provided by financing activities		943			3,648
Investing activities
Additions to leasehold improvements and equipment		-			(74	)
Net cash used in investing activities		-			(74	)
(Decrease) increase in cash		(1,913	)		1,312
Effect of foreign exchange on cash		403			(2	)
Cash
Beginning of period		2,282			1,210
End of period	$	772		$	2,520

See accompanying notes

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

1. Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal and recurring nature.

These financial statements should be read in conjunction with the audited consolidated financial statements at December 31, 2023. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. IntelGenx Technologies Corp. (and collectively with IntelGenx Corp., our wholly-owned Canadian subsidiary, "IntelGenx" or the "Company") prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America ("USA"). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.

The consolidated financial statements include the accounts of IntelGenx Technologies Corp. and IntelGenx Corp. On consolidation, all inter-entity transactions and balances have been eliminated.

The financial statements are expressed in U.S. funds.

Management has performed an evaluation of the Company's activities through the date and time these financial statements were issued and concluded that there are no additional significant events requiring recognition or disclosure.

2. Going Concern

The Company has financed its operations to date primarily through public offerings of its common stock, proceeds from issuance of convertible notes and debentures, bank loans, royalty, up-front and milestone payments, license fees, proceeds from exercise of warrants and options, and research and development revenues. The Company has devoted substantially all of its resources to its drug development efforts, conducting clinical trials to further advance the product pipeline, the expansion of its facilities, protecting its intellectual property and general and administrative functions relating to these operations. The future success of the Company is dependent on its ability to develop its product pipeline and ultimately upon its ability to attain profitable operations. As of March 31, 2024, the Company had approximately $772,000 in cash. The Company does not have sufficient existing cash to support operations for the next year following the issuance of these financial statements. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Therefore, management plans to explore any available strategic alternatives.

Depending on the strategic alternatives available and if the Company is unable to raise further capital when needed or on attractive terms, or if it is unable to procure partnership arrangements to advance its programs, the Company would be forced to potentially delay, reduce or eliminate some of its research and development programs and commercial activities.

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The accompanying consolidated financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern. Should the Company be unable to continue as a going concern, it may be unable to realize the carrying value of its assets and to meet its liabilities as they become due.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

3. Significant Accounting Policies

Revenue Recognition

The Company may enter into licensing and collaboration agreements for product development, licensing, supply and manufacturing for its product pipeline. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations. These contracts are analyzed to identify all performance obligations forming part of these contracts. The transaction price of the contract is then determined. The transaction price is allocated between all performance obligations on a residual standalone selling price basis. The stand-alone selling price is estimated based on the comparable market prices, expected cost plus margin and the Company's historical experience.

Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer.

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue.

The following is a description of principal activities - separated by nature - from which the Company generates its revenue.

Product revenue

The Company recognizes revenue from the sale of its products when the following conditions are met; delivery has occurred; the price is fixed or determinable; the collectability is reasonable assured and persuasive evidence of an arrangement exists.

Research and Development Revenue

Revenues with corporate collaborators are recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

3. Summary of Significant Accounting Policies (Cont'd)

Licensing and Collaboration Arrangements

Licenses are considered to be right-to-use licenses. As such, the Company recognizes the licenses revenues at a point in time, upon granting the licenses.

Milestone payments are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, research and other revenues in the period during which the adjustment is recognized. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is significant risk that the Company may not earn all of the milestone payments for each of its contracts.

Royalties are typically calculated as a percentage of net sales realized by the Company's licensees of its products (including their sub-licensees), as specifically defined in each agreement. The licensees' sales generally consist of revenues from product sales of the Company's product pipeline and net sales are determined by deducting the

following: estimates for chargebacks, rebates, sales incentives and allowances, returns and losses and other customary deductions in each region where the Company has licensees. Revenues arising from royalties are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved.

Leasehold Improvements and Equipment

Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:

On the declining balance method -

Laboratory and office equipment	20%
Computer equipment	30%

On the straight-line method -

Leasehold improvements	over the lease term
Manufacturing equipment	5 - 10 years

Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

3. Summary of Significant Accounting Policies (Cont'd)

Leases

Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria.

Substantially all of the Company's operating leases are comprised of office space and property leases. The finance leases are comprised of laboratory equipment leases.

For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease.

The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured as the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's secured incremental borrowing rate for the same term as the underlying lease.

Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early.

Lease modifications result in remeasurement of the lease liability.

Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability.

The Company has elected not to recognize right-of-use assets and lease liabilities for short-tern leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material.

4. Inventory

Inventory as at March 31, 2024 consisted of raw materials in the amount of $173,000 (2023 - $71,000).

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

5. Leasehold Improvements and Equipment

						2024		2023
				Accumulated		Net Carrying		Net Carrying
		Cost		Depreciation		Amount		Amount
Manufacturing equipment	$	4,675,000	$	2,058,000	$	2,617,000	$	2,755,000
Laboratory and office equipment		1,582,000		1,229,000		353,000		382,000
Computer equipment		157,000		131,000		26,000		29,000
Leasehold improvements		3,286,000		2,600,000		686,000		792,000
	$	9,700,000	$	6,018,000	$	3,682,000	$	3,958,000

As at March 31, 2024, no depreciation has been recorded on manufacturing equipment in the amount of $1,793,000 (2023 - $1,838,000) as this equipment is not yet in use.

6. Bank Indebtedness

The Company's credit facility is subject to review annually and consists of corporate credits cards of up to CAD$50,000 ($37,000) and $30,000, and foreign exchange contracts limited to CAD$425,000 ($314,000).

7. Convertible Notes

Current liabilities

On October 15, 2020, the Company announced the closing of an offering by way of private placement to certain investors in the United States of $1.2 million principal amount of 8% convertible notes due October 15, 2024. The Notes will bear interest at a rate of 8% per annum, payable quarterly, and will be convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.18 per Share. The Company intends to use the proceeds of the Offering for working capital purposes. In connection with the Offering, the Company paid to an agent a cash commission of approximately $85,000 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 482,000 common shares at a price of $0.18 per Share until October 15, 2022.

On October 23, 2020, the Company announced the closing of a second tranche of the Notes to certain investors in the United States of $557,000 principal amount of 8% convertible notes due Oct 15, 2024. The Notes bear interest at a rate of 8% per annum, payable quarterly, and are convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.18 per Share. In connection with the Offering, the Company paid to an agent a cash commission of approximately $39,000 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 222,800 common shares at a price of $0.18 per Share until October 15, 2022.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

7. Convertible Notes (Cont'd)

Management has determined the value of the agents' warrants to be $44,000.

The convertible notes have been recorded as a liability. Total transactions costs in the amount of $268,000 were recorded against the liability. The accretion expense for the three-month period ended March 31, 2024 amounts to $18,000 (2023: $16,000). The warrants have been recorded as equity.

The components of the convertible notes are as follows:

		March 31, 2024		December 31, 2023
Attributed value of net proceeds to convertible notes	$	1,397,000	$	1,397,000
Accretion		211,000		193,000
Convertible note	$	1,608,000	$	1,590,000

The interest on the convertible notes for the three-month period ended March 31, 2024 amounts to $33,000 (2023: $33,000). The interest is recorded in financing and interest expense.

On May 8, 2018, the Company closed its previously announced offering by way of private placement (the "Offering"). In connection with the Offering, the Company issued 320 units (the "Units") at a subscription price of $10,000 per Unit for gross proceeds of $3,200,000. A related party of the Company participated in the Offering and subscribed for an aggregate of two Units.

Each Unit is comprised of (i) 7,940 common shares of the Corporation ("Common Shares"), (ii) a $5,000 convertible 6% note (a "Note"), and (iii) 7,690 warrants to purchase common shares of the Corporation ("Warrants"). Each Note bears interest at a rate of 6% (payable quarterly, in arrears, with the first payment being due on September 1, 2018), matured on June 1, 2021 and is convertible into Common Shares at a conversion price of $0.80 per Common Share. Each Warrant entitles its holder to purchase one Common Share at a price of $0.80 per Common Share until June 1, 2021.

In connection with the Offering, the Company paid to the Agents a cash commission of approximately $157,800 in the aggregate and issued non-transferable agents' warrants to the Agents, entitling the Agents to purchase 243,275 common shares at a price of $0.80 per share until June 1, 2021. Management has determined the value of the agents' warrants to be $50,000.

The proceeds of the Units are attributed to liability and equity components based on the fair value of each component as follows:

		Gross proceeds		Transaction costs		Net proceeds

Common stock	$	1,627,000	$	167,000	$	1,460,000
Convertible notes		1,086,000		111,000		975,000
Warrants		487,000		50,000		437,000
	$	3,200,000	$	328,000	$	2,872,000

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

7. Convertible Notes (Cont'd)

On May 19, 2021, the noteholders approved the amendment of the terms of the convertible notes. The maturity date of the convertible notes was extended from June 1, 2021 to October 31, 2024, the interest rate of the notes increased from 6% to 8%, and the conversion price was reduced from $0.80 to $0.44. These amendments were accounted for as an extinguishment and the notes were re-measured at fair value on June 1, 2021. This re-measurement resulted in a gain on extinguishment in the amount of $151,000 recognized in finance and interest income.

The components of the convertible notes subsequent to the amendments are as follows:

		March 31, 2024			December 31, 2023
Face value of the convertible notes	$	909,000		$	909,000
Transaction costs		(29,000	)		(29,000	)
Accretion		97,000			87,000
Convertible notes	$	977,000		$	967,000

The convertible notes have been recorded as a liability. Total transactions costs in the amount of $29,000 were recorded against the liability. The accretion expense for the three-month period ended March 31, 2024 amounts to $10,000 (2023: $8,000).

The interest on the convertible notes for the three-month period ended March 31, 2024 amounts to $20,000 (2023: $20,000) and is recorded in financing and interest expense.

Long-term liabilities

On August 31, 2023 the Company announced the closing of the first tranche of a non-brokered private placement (the "Offering") of units ("Units") from atai for aggregate gross proceeds of approximately US$3 million, including US$750,000 received by the Company pursuant to the Subsequent atai Subscription (as defined below) upon Shareholder Approvals (as defined below).

Pursuant to the Offering, (i) United States subscribers can subscribe for Units (the "US Units") at a price of US$1,000 per US Unit, each US Unit being comprised of a US$1,000 principal amount convertible promissory note (the "US Notes") and 5,405 common stock purchase warrants (the "US Warrants").

The US Notes are convertible into shares of common stock of the Company (the "Shares") at the option of the holder at a price of US$0.185 (the "US Conversion Price"), at anytime from the date that is six (6) months following their issuance up to and including August 31, 2026, and bear interest at 12% per annum, payable quarterly, in arrears, with first payment due September 30, 2023 and every 3 months thereafter. The US Warrants entitle the holders thereof to purchase Shares at a price of US$0.26 per Share, for a period of 3 years following their issuance.

atai, a significant shareholder and partner of the Company, subscribed for 2,220 US Units for aggregate gross proceeds to the Company of US$2,220,000 (the "Initial atai Proceeds"). In addition, atai committed to subscribe for an additional 750 US Units for additional aggregate proceeds to the Company of US$750,000 (collectively with the Initial atai Proceeds, the "atai Proceeds") on the same terms (the "Subsequent atai Subscription"), subject to the Company obtaining the Shareholder Approvals, which it did on November 28, 2023.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

7. Convertible Notes (Cont'd)

On September 30, 2023, the Company and atai agreed, subject to obtaining TSX approval and the Shareholder Approvals, to enter into an amendment (the "Subscription Agreement Amendment") to the subscription agreement entered into by and between the Company and atai in connection with the Offering to provide atai with the right (the "Call Option") to purchase up to an additional 7,401 US Units (the "Call Option Units") at any time prior to August 31, 2026. The Call Option Units, to the extent atai exercises the Call Option in whole or in part, will be issued on the same terms as the US Units, including with respect to the US Conversion Price, maturity date, interest rate and the number of warrants issued in connection therewith. The Subscription Agreement Amendment will provide that the issuance of any Call Option Units will result in a corresponding reduction in atai's remaining purchase right pursuant to the amended and restated securities purchase agreement dated May 14, 2021, which such right to be reduced by the number of Shares issuable upon the conversion of the principal amount outstanding under such issued Call Option Units.

IntelGenx intends to use the proceeds of the Offering to fund the Company's wholly-owned Canadian subsidiary, continuing formulation and development efforts related to ongoing collaborations between IGXT and atai as well as working capital and expenses related to the Offering.

The proceeds of the Units are attributed to liability and equity components based on the fair value of each component as follows:

		Gross proceeds		Transaction costs		Net proceeds

Convertible notes	$	1,969,000	$	169,000	$	1,800,000
Warrants		1,001,000		89,000		912,000
	$	2,970,000	$	258,000	$	2,712,000

The convertible notes have been recorded as a liability. Total transactions costs in the amount of $169,000 were recorded against the liability. The accretion expense for the three-month period ended March 31, 2024 amounts to $67,000 (2023: $Nil). The warrants have been recorded as equity.

The components of the convertible notes are as follows:

		March 31, 2024		December 31, 2023

Attributed value of net proceeds to convertible notes	$	1,800,000	$	1,800,000
Accretion		134,000		67,000
Convertible notes	$	1,934,000	$	1,867,000

The interest on the convertible notes for the three-month period ended March 31, 2024 amounts to $90,000 (2023: $Nil) and is recorded in financing and interest expense.

The proceeds of the Units are attributed to liability and equity components based on the fair value of each component. Management has determined the value attributed to the warrants to be $912,000.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

7. Convertible Notes (Cont'd)

On March 21, 2023, the Company announced the closing of an offering by way of private placement to certain investors in the United States of $763,000 principal amount of 10% convertible notes due March 1, 2027. The Notes will bear interest at a rate of 10% per annum, payable quarterly, and will be convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.20 per Share. The Company intends to use the proceeds of the Offering to finance the Company's Rizaport and Buprenorphine programs as well as for working capital. In connection with the Offering, the Company paid to an agent a cash commission of approximately $53,000 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 304,000 common shares at a price of $0.20 per Share until March 21, 2025.

Management has determined the value of the agents' warrants to be $19,000.

The convertible notes have been recorded as a liability. Total transactions costs in the amount of $126,000 were recorded against the liability. The accretion expense for the three-month period ended March 31, 2024 amounts to $7,000 (2023: $1,000). The warrants have been recorded as equity.

The components of the convertible notes are as follows:

		March 31, 2024			December 31, 2023

Face value of the convertible notes	$	763,000		$	763,000
Transaction costs		(126,000	)		(126,000	)
Accretion		26,000			19,000
Convertible notes	$	663,000		$	656,000

The interest on the convertible notes for the three-month period ended March 31, 2024 amounts to $19,000 (2023: $2,000) and is recorded in financing and interest expense.

On August 5, 2021, the Company announced the closing of an offering by way of private placement to certain investors in the United States of $2.1 million principal amount of 8% convertible notes due July 31, 2025. The Notes bear interest at a rate of 8% per annum, payable quarterly, and are convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.40 per Share. The Company intends to use the proceeds of the Offering for the Montelukast clinical program. In connection with the Offering, the Company paid to an agent a cash commission of approximately $199,525 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 613,000 common shares at a price of $0.40 per Share until August 4, 2023. On May 8, 2023, the expiry date of these warrants was extended by an additional 12 months to August 4, 2024. The impact of the modification on the financial statements was insignificant.

Management has determined the value of the agents' warrants to be $164,000.

The convertible notes have been recorded as a liability. Total transactions costs in the amount of $403,000 were recorded against the liability. The accretion expense for the three-month period ended March 31, 2024 amounts to $26,000 (2023: $23,000). The warrants have been recorded as equity.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

7. Convertible Notes (Cont'd)

The components of the convertible notes are as follows:

		March 31, 2024			December 31, 2023
Face value of the convertible notes	$	2,101,000		$	2,101,000
Transaction costs		(403,000	)		(403,000	)
Accretion		243,000			217,000
Convertible notes	$	1,941,000		$	1,915,000

The interest on the convertible notes for the three-month period ended March 31, 2024 amounts to $42,000 (2023: $42,000) and is recorded in financing and interest expense.

8. Term loan

On December 5, 2023, atai Life Sciences ("atai") has granted to the Company a secured term loan for $500,000, bearing interest at 14%. Principal of and interest on this Term Loan from time to time outstanding shall be due and payable from thirty five percent (35%) of the proceeds of each closing of equity financing until the principal balance and any outstanding balance is paid in full. Regardless of whether any closing of equity financing occurs, the outstanding and remaining principal balance and interest on this term loan shall be due and payable by December 31, 2024. The interest for the three-month period ended March 31, 2024 amounts to $18,000 and is recorded in financing and interest expense (2023 - $Nil).

9. Loan Payable

Current liabilities

atai Life Sciences ("atai") has granted to the Company a secured loan in the amount of $8,500,000, bearing interest at 8%. The loan is guaranteed by the Company and secured by all present and future movable property, rights and assets of the Company, excluding any intellectual property or technology controlled or owned by the Company.

On August 31, 2023, the Company entered into an amending agreement (the "Amending Agreement") in respect of the amended and restated loan agreement dated as of September 14, 2021 (the "Loan Agreement") between the Company, as borrower, and atai, as lender pursuant to which, among other things, the maturity date of the Loan Agreement was extended from January 5, 2024 to January 5, 2025, and the Company granted additional security to atai over any non-licensed intellectual property of the Company (the "Loan Amendment"). The transaction is accounted for as a modification. The impact of the modification on the financial statements was insignificant.

On September 30, 2023, the Company and atai also agreed, subject to obtaining TSX and Shareholder approvals, to enter into a second amendment to the Loan Agreement (the "Second Amendment") to provide, among other things, for the ability for atai to convert the principal and accrued interest outstanding under the Loan Agreement into Shares. On November 28, 2023, the Company announced shareholder approvals of the financing transactions. As a result, atai has the ability to convert the principal and accrued interest under the Loan Agreement into shares of common stock of the Company (the "Shares") at a price of US$0.185 (the "US Conversion Price"). This transaction is accounted for as an extinguishment and the debt was re-measured at fair value on November 28, 2023. This re-measurement resulted in a gain on extinguishment in the amount of $1,148,000 recognized in finance and interest income.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

9. Loan Payable (Cont'd)

The loan bears interest at 8% and is convertible into shares of common stock of the Company. The interest for the three-month period ended March 31, 2024 amounts to $170,000 and is recorded in financing and interest expense (2023 - $164,000). As at March 31, 2024, the Company has accrued interest expense totalling $1,419,000 (2023: $1,249,000). The accretion expense for the three-month period ended March 31, 2024 amounts to $248,000 (2023: $Nil).

The components of the Company's debt subsequent to the extinguishment are as follows

		March 31, 2024			December 31, 2023

Attributed value of the loan payable	$	7,352,000		$	7,352,000
Transaction costs		(37,000	)		(37,000	)
Accretion		334,000			86,000
Loan payable		7,649,000		$	7,401,000

Long-term liabilities

On March 11, 2024, the Company announced that it entered into a third amended and restated loan agreement dated as of March 8, 2024 (amending the second amended and restated loan agreement dated as of September 30, 2023) (the "Loan Agreement") with atai, pursuant to which, among other things, atai has agreed to make (i) one (1) additional term loan in the amount of US$1,000,000, which was disbursed within three (3) business days of the execution of the Loan Agreement (the "First Tranche Loan"), and (ii) one (1) additional term loan in the amount of US$1,000,000, which loan was disbursed subsequent to the end of the quarter on April 19, 2024 (the "Second Tranche Loan" and collectively with the Second Tranche Loan, the "Additional Term Loans"). The Additional Term Loans will mature on February 1, 2026.

The Loan Agreement provides for the ability for atai to convert (the "Conversion Feature"), from time to time, (i) the principal outstanding under the First Tranche Loan into shares of common stock of the Company (the "Shares") at a conversion price of US$0.185 per Share (the "Conversion Price"), and (ii) the principal outstanding under the Second Tranche Loan into Shares at a conversion price equal to the greater of (a) the Conversion Price and (b) the 5-day volume-weighted average price (the "5-day VWAP") of the Shares on the TSX ending on the day preceding the disbursement by atai of the Second Tranche Loan to the Company or IntelGenx, less the maximum permissible discount under the applicable TSX rules.

Additionally, the Company may elect, with the consent of atai, to pay any accrued but unpaid interest on the Additional Term Loans in Shares at a price per Share equal to the 5-day VWAP of the Shares ending on the day that is the second business day before the day the interest becomes due and payable, less the maximum permissible discount under the applicable TSX rules.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

9. Loan Payable (Cont'd)

Concurrently to entering into the Loan Agreement, the Company has issued 4,000,000 warrants (the "Warrants") to atai. The Warrants entitle atai to purchase Shares at a price of US$0.17 per Share, for a period of 36 months following their issuance.

The proceeds of the loan are attributed to liability and equity components based on the fair value of each component as follows:

		Gross proceeds		Transaction costs		Net proceeds

Loan payable	$	689,000	$	24,000	$	665,000
Warrants		311,000		11,000		300,000
	$	1,000,000	$	35,000	$	965,000

The loan payable has been recorded as a liability. Total transactions costs in the amount of $24,000 were recorded against the liability. The accretion expense for the three-month period ended March 31, 2024 amounts to $5,000 (2023: $Nil). The warrants have been recorded as equity.

The components of the loan payable are as follows:

		March 31, 2024

Attributed value of net proceeds to loan payable	$	689,000
Transaction costs		(24,000	)
Accretion		5,000
Loan payable	$	670,000

The interest on the loan payable for the three-month period ended March 31, 2024 amounts to $7,000 (2023: $Nil) and is recorded in financing and interest expense.

The proceeds of the loan are attributed to liability and equity components based on the fair value of each component. Management has determined the value attributed to the warrants to be $311,000.

Atai is an insider of the Company as a result of its beneficial ownership of, or control or discretion over, directly or indirectly, greater than 10% of the outstanding Shares.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

10. Capital Stock

On November 28, 2023, the shareholders of the Company approved an amendment to increase the total number of authorized shares of capital stock of the Company from 470,000,000 to 600,000,000 and to increase the total authorized shares of the Company's common stock at $0.00001 par value, from 450,000,000 shares to 580,000,000 shares.

11. Additional Paid-In Capital

Stock options

On January 29, 2024, 1,250,000 options to purchase common stock were granted to employees under the 2022 Stock Option Plan. The options have an exercise price of $0.14. The options granted vest over a period of 2 years at a rate of 25% every six months and expire 10 years after the grant date. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $132,000.

On January 29, 2024, the Company granted 200,000 options to purchase common stock to a consultant. The options have an exercise price of $0.14. The options granted vest over 2 years at a rate of 25% every six months and expire 3 years after the grant date. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $13,000.

On January 29, 2023, 310,000 options to purchase common stock were granted to employees under the 2022 Stock Option Plan. The options have an exercise price of $0.24. The options granted vest over a period of 4 years at a rate of 25% every twelve months and expire 10 years after the grant date. These options may have accelerated vesting if specific market conditions are met. The market conditions are based on the Company's stock price achieving specified targets over a continuous period of 30 calendar days. If the market conditions are met, the options will immediately vest and become exercisable. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $55,000.

No stock options were exercised during the three-month periods ended March 31, 2024 and 2023.

Compensation expenses for stock-based compensation of $103,000 and $11,000 were recorded during the three-month periods ended March 31, 2024 and 2023, respectively. An amount of $102,000 (2023 - $8,000) expensed in the three-month period ended March 31, 2024 relates to stock options granted to employees and an amount of $1,000 (2023 - $3,000) relates to stock options granted to a consultant. As at March 31, 2024, the Company has $514,000 of unrecognized stock-based compensation.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

11. Additional Paid-In Capital (Cont'd)

Warrants

No warrants were exercised during the three-month periods ended March 31, 2024 and 2023.

Deferred Share Units ("DSUs")

On January 25, 2024, 1,250,000 DSUs have been granted under the DSU Plan, accordingly, an amount of $185,000 has been recognized in general and administrative expenses.

On January 29, 2023, 781,250 DSUs have been granted under the DSU Plan, accordingly, an amount of $185,000 has been recognized in general and administrative expenses.

During the three-month period ended March 31, 2024, 454,890 DSUs were converted back into a cash amount of CAD $98,000 (73,000) and paid to the director.

Performance and Restricted Share Units ("PRSUs")

On January 29, 2023, the Company granted 350,000 Performance Restricted Share Units to certain employees, which vest if certain market conditions are met. The PRSUs vest based on the achievement of specified market conditions over a performance period of 3 years. The market conditions are based on the Company's stock price achieving specified targets over a continuous period of 30 calendar days. If the market conditions are met, the PRSUs will vest and become payable in shares of the Company's common stock.

The PRSUs were accounted for at their fair value, as determined by the Binomial Lattice valuation model, of approximately $23,000. As at March 31, 2024, an amount of $2,000 has been recognized as stock-based compensation in general and administrative expenses (2023 - $Nil).

No PRSUs were granted during the three-month period ended March 31, 2023.

On January 29, 2024, 1,354,268 rewards have been issued under the RSU Plan having a fair value of $190,000. As at March 31, 2024, an amount of $190,000 has been recognized as stock-based compensation in general and administrative expenses. The RSUs expire 3 years after the grant date.

On April 4, 2023, 100,000 rewards have been issued under the RSU Plan having a fair value of $18,000. As at March 31, 2024, an amount of $5,000 has been recognized as stock-based compensation in general and administrative expenses. The RSUs expire 5 years after the grant date.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

12. Revenues

The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:

		March 31, 2024		March 31, 2023


Research and development agreements	$	169,000	$	162,000
Royalties on product sales		5,000		-
	$	174,000	$	162,000

The following table presents our revenues disaggregated by timing of recognition:

		March 31, 2024		March 31, 2023

Product and services transferred at point in time	$	5,000	$	-
Products and services transferred over time		169,000		162,000
	$	174,000	$	162,000

The following table presents our revenues disaggregated by geography, based on the billing addresses of our customers:

		March 31, 2024		March 31, 2023
Europe	$	112,000	$	162,000
United States		62,000		-
	$	174,000	$	162,000

Remaining performance obligations

As at March 31, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligation is $3,347,000 representing research and development agreements. The Company is also eligible to receive up to $2,411,000 in research and development milestone payments, approximately 100% of which is expected to be recognized in the next three years; up to $395,000 in commercial sales milestone payments which are wholly dependent on the marketing efforts of our development partners. In addition, the Company is entitled to receive royalties on potential sales.

The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about the remaining performance obligations that have original expected durations of one year or less.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

13. Leases

Operating leases

Substantially all our operating lease right-of-use assets and operating lease liability represents leases for office space and property to conduct our business.

The operating lease expense for the three-month period ended March 31, 2024 included in general and administrative expenses is $65,000. The cash outflows from operating leases for the three-month period ended March 31, 2024 was $67,000.

The weighted average remaining lease term and the weighted average discount rate for operating leases at March 31, 2024 were 1.9 years and 10%, respectively.

The following table reconciles the undiscounted cash flows for the operating leases as at March 31, 2024 to the operating lease liabilities recorded on the balance sheet:

		Operating Leases

2024		200,000
2025		267,000
2026		44,000
Total undiscounted lease payments		511,000
Less: Interest		99,000
Present value of lease liabilities	$	412,000

Current portion of operating lease liability	$	242,000
Operating lease liability	$	170,000

Finance leases

Substantially all our finance lease right-of-use assets and finance lease liability represents leases for laboratory equipment to conduct our business.

The cash outflows from finance leases for the three-month period ended March 31, 2024 was $22,000 (2023: $9,000).

The weighted average remaining lease term and the weighted average discount rate for finance leases at March 31, 2024 were 1.2 years and 3.75%, respectively.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
March 31, 2024
(Expressed in U.S. Funds)
(Unaudited)

13. Leases (Cont'd)

The following table reconciles the undiscounted cash flows for the finance leases as at March 31, 2024 to the finance lease liabilities recorded on the balance sheet:

		Finance Leases

2024	$	68,000
2025		36,000
Total undiscounted lease payments		104,000
Less: Interest		2,000
Present value of lease liabilities	$	102,000

Current portion of finance lease liability	$	82,000
Finance lease liability	$	20,000

14. Related Party Transactions

Included in management salaries are $101,000 (2023 - $2,000) for options, PRSUs and RSUs granted to key management personnel under the 2022 Stock Option Plan and $44,000 for RSUs granted to non-employee directors. The Company considers its Chief Executive Officer, President and Chief Financial Officer, and Vice-Presidents to be key management personnel.

Also included in general and administrative expenses for the three-month period ended March 31, 2024 are director fees of $68,000 (2023: $57,000).

The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties.

15. Basic and Diluted Loss Per Common Share

Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants, share-based compensation and convertible debenture and notes have been excluded from the calculation of diluted loss per share since they are anti-dilutive.

16. Contingencies

The government authorities have assessed the Company with respect to sales taxes claimed on certain expenses between 2017 and 2020, which the government is denying. The sales tax assessments amount to $314,000 (including interest and penalties of $34,000), which was paid to avoid further interest and penalties. The Company disagrees with the government's position and the sales tax assessments are under appeal. In the event the Company is unsuccessful in its appeal, sales taxes expenses would increase by $280,000 and net earnings would decrease by $280,000.

Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations

Introduction to Management's Discussion and Analysis

This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") comments on our business operations, performance, financial position and other matters for the three-month periods ended March 31, 2024 and 2023.

Unless otherwise indicated, all financial and statistical information included herein relates to continuing operations of the Company. Unless otherwise indicated or the context otherwise requires, the words, "IntelGenx, "Company", "we", "us", and "our" refer to IntelGenx Technologies Corp. and its subsidiaries, including IntelGenx Corp.

This MD&A should be read in conjunction with the accompanying unaudited Consolidated Financial Statements and Notes thereto. We also encourage you to refer to the Company’s MD&A for the year ended December 31, 2023. In preparing this MD&A, we have taken into account information available to us up to May 15, 2024, the date of this MD&A, unless otherwise indicated.

Additional information relating to the Company, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "2023 Form 10-K"), is available on SEDAR at www.sedar.com and on the U.S. Securities and Exchange Commission (the "SEC") website at www.sec.gov.

All dollar amounts are expressed in U.S. dollars, unless otherwise noted.

Cautionary Statement Concerning Forward-Looking Statements

Certain statements included or incorporated by reference in this MD&A constitute forward-looking statements within the meaning of applicable securities laws. All statements contained in this MD&A that are not clearly historical in nature are forward-looking, and the words "anticipate", "believe", "continue", "expect", "estimate", "intend", "may", "plan", "will", "shall" and other similar expressions are generally intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All forward-looking statements are based on our beliefs and assumptions based on information available at the time the assumption was made. These forward-looking statements are not based on historical facts but on management's expectations regarding future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Forward-looking statements involve significant known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those implied by forward-looking statements. These factors should be considered carefully and you should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this MD&A or incorporated by reference herein are based upon what management believes to be reasonable assumptions, there is no assurance that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this MD&A or as of the date specified in the documents incorporated by reference herein, as the case may be. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which such statements were made or to reflect the occurrence of unanticipated events, except as may be required by applicable securities laws. The factors set forth in Item 1A., "Risk Factors" of the 2023 Form 10-K, as well as any cautionary language in this MD&A, provide examples of risks, uncertainties and events that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. Before you invest in the common stock, you should be aware that the occurrence of the events described as risk factors and elsewhere in this report could have a material adverse effect on our business, operating results and financial condition.

Company Background

We are a drug delivery company established in 2003 and headquartered in Montreal, Quebec, Canada. Our focus is on the contract development and manufacturing of novel oral thin film products for the pharmaceutical market. More recently, we have made the strategic decision to enter the psychedelic market by entering into a strategic partnership agreement with atai Life Sciences. The Company has applied and is operating under a contract development and manufacturing organization ("CDMO") business model. As a full-service CDMO, we are offering partners a comprehensive portfolio of pharmaceutical services, including pharmaceutical research and development ("R&D"), clinical monitoring, regulatory support, tech transfer, manufacturing scale-up and commercial manufacturing.

Our business strategy is to leverage our proprietary drug delivery technologies and develop pharmaceutical products with tangible benefits for patients, for our partners and, once a developed product launches, retain the exclusive manufacturing rights.

Our primary growth strategy is based on providing CDMO services to the pharmaceutical industry. In order to successfully execute our business strategy, it will be essential to create and maintain a fully compliant manufacturing environment capable of meeting customer expectations regarding cGMP compliance and manufacturing capacity.

We have undertaken a strategy under which we will work with pharmaceutical companies in order to apply our oral film technology to pharmaceutical products for which patent protection is nearing expiration, a strategy which is often referred to as "lifecycle management." Under Section 505(b)(2) of the Federal Food, Drug, and Cosmetics Act (the "FDCA") ("Section 505(b)(2)"), the U.S. Food and Drug Administration (the "FDA") may grant market exclusivity for a term of up to three years following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage, dosage form, route of administration or a combination.

The Section 505(b)(2) pathway is also the regulatory approach to be followed if an applicant intends to file an application for a product containing a drug that is already approved by the FDA for a certain indication and for which the applicant is seeking approval for a new indication or for a new use, the approval of which is required to be supported by new clinical trials, other than bioavailability studies. We have implemented a strategy under which we actively look for such so-called "repurposing opportunities" and determine whether our proprietary VersaFilm™ technology adds value to the product. We currently have two such drug repurposing projects in our development pipeline.

We continue to develop the existing products in our pipeline and may also perform R&D on other potential products as opportunities arise.

We have established a state-of-the-art manufacturing facility with the intent to manufacture all of our VersaFilm™ products in-house as we believe that this:

• represents a profitable business opportunity;

• will reduce our dependency upon third-party contract manufacturers, thereby protecting our manufacturing process know-how and intellectual property; and

• allows us to offer our clients and development partners a full service from product conception through to supply of the finished product.

We initiated a project to expand the existing manufacturing facility, the timing of which will be dictated in part by the completion of agreements with our commercial partners. This expansion might become necessary in order to meet expected production volumes from our commercial partners. The new facility should create a fourfold increase of our production capacity in addition to offering a one-stop shopping opportunity to our partners and provide better protection of our Intellectual Property.

Technology Platforms

Our main product development efforts are based upon three delivery platform technologies: (1) VersaFilm™, an oral film technology, (2) the VetaFilm^TM technology platform for veterinary applications, and (3) DisinteQ^TM a disintegrating oral film technology.

VersaFilm™ is a drug delivery platform technology that enables the development of oral thin films, improving product performance through:

• rapid disintegration without the need for water;

• quicker buccal or sublingual absorption;

• potential for faster onset of action and increased bioavailability;

• potential for reduced adverse effects by bypassing first-pass metabolism;

• easy administration for patients who have problems swallowing tablets or capsules; pediatric and geriatric patients as well as patients who fear choking and/or are suffering from nausea (e.g., nausea resulting from chemotherapy, radiotherapy or any surgical treatment);

• pleasant taste; and

• small and thin size, making it convenient for consumers.

Our VersaFilm™ technology consists of a thin (25-35 micron) polymeric film comprised of United States Pharmacopeia components that are approved by the FDA for use in food, pharmaceutical, and cosmetic products. Derived from the edible film technology used for breath strips and initially developed for the instant delivery of savory flavors to food substrates, the VersaFilm™ technology is designed to provide a rapid response and improved bioavailability compared to existing conventional tablets. Our VersaFilm™ technology is intended for indications requiring rapid onset of action, such as migraine, opioid dependence, chronic pain, motion sickness, erectile dysfunction, and nausea or for drug that have a low oral bioavailability and require transmucosal absorption.

Our VetaFilm™ platform technology is designed for the application in companion animals. Dose acceptance and compliance are often a challenge for the care giver which can be overcome with our newly designed VetaFilm™ platform. VetaFilm™ is specifically formulated with flavors that are appealing to pets and to achieve rapid adhesion to the oral mucosa of the animal to achieve compliance.

Our DISINTEQ™ oral disintegrating film formulations will provide different dissolution characteristics compared to VersaFilm®. Instead of quickly dissolving in the oral cavity, DISINTEQ™ formulations disintegrate at a controlled rate. This will allow a slower release of the drug into the oral cavity thereby avoiding saturation of the oral mucosal membranes and increasing mucosal absorption.

Product Opportunities that provide Tangible Patient Benefits

We offer our services to develop oral film products leveraging our VersaFilm™ technology that provide tangible patient benefits versus existing drug delivery forms. Patients with difficulties swallowing medication, pediatrics or geriatrics may benefit from oral films due to the ease of use. Similarly, we are working on oral films to improve bio-availability and/or response time versus existing drugs and thereby reducing side effects. We have also identified the Animal Health sector, particularly the companion animal segment, as an area where our proprietary oral film technology can significantly improve the administration of medication to animals.

Development of New Drug Delivery Technologies

The rapidly disintegrating film technology contained in our VersaFilm™, is an example of our efforts to develop alternate technology platforms. As we work with various partners on different products, we seek opportunities to develop new proprietary technologies.

Most recent key developments

On February 5, 2024, the Company announced positive results from a proof-of-concept ("POC") study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx's VetaFilm™ platform in healthy dogs and cats. The POC study was conducted through a research collaboration with the University of Prince Edward Island, one of North America's leading veterinary universities.

On February 20, 2024, the Company announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock ("Series A Preferred Stock"), par value $0.00001 per share, at an offering price of $10.00 per share (the "Offering"), for a maximum Offering amount of $20,000,000.

Holders of the Series A Preferred Stock will be entitled to receive cumulative dividends in the amount of $0.20 per share each quarter, or 8% per year. Each share of Series A Preferred Stock will be convertible into twenty (20) shares of our common stock ("Common Stock) at the option of the holder, subject to certain conditions in accordance with the requirements of the Toronto Stock Exchange. Commencing on the fifth anniversary of the initial closing of this offering and continuing indefinitely thereafter, the Company shall have a right to call for redemption the outstanding shares of the Series A Preferred Stock at a call price equal to 150% of the original issue price of the Series A Preferred Stock, and correspondingly, each holder of shares of the Series A Preferred Stock shall have a right to sell the shares of Series A Preferred Stock held by such holder back to the Company at a price equal to 150% of the original issue purchase price of such shares. The Series A Preferred Stock being offered will rank, as to dividend rights and rights upon the Company's liquidation, dissolution, or winding up, senior to the Common Stock.

On March 11, 2024, the Company announced that it entered into a third amended and restated loan agreement dated as of March 8, 2024 (amending the second amended and restated loan agreement dated as of September 30, 2023) (the "Loan Agreement") with atai, pursuant to which, among other things, atai has agreed to make (i) one (1) additional term loan in the amount of US$1,000,000, which loan was disbursed within three (3) business days of the execution of the Loan Agreement (the "First Tranche Loan"), and (ii) one (1) additional term loan in the amount of US$1,000,000, which loan was disbursed subsequent to the end of the quarter on April 19, 2024, upon the achievement of a pre-defined milestone (the "Second Tranche Loan" and collectively with the Second Tranche Loan, the "Additional Term Loans"). The Additional Term Loans will mature on February 1, 2026.

Subsequent to the end of the quarter, on April 5, 2024, the Company announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC ("Xiromed"), has received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding its resubmitted abbreviated new drug application ("ANDA") for Buprenorphine Buccal Film.

The CRL includes a request for additional Pharmaceutical Quality information. The FDA confirmed that no additional inspection of IntelGenx's facility is required at this time.

Subsequent to the end of the quarter, on April 8, 2024, the Company announced that that Montelukast VersaFilm^TM has been administered to the first Parkinson's Disease ("PD") patients in the Phase 2 ('MONTPARK') clinical trial.

MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm^TM or placebo twice daily for 18-months, followed by a 3-month washout period. Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents. MONTPARK is being conducted at the Karolinska University Hospital and at three other Swedish University affiliated institutions under IntelGenx's previously announced research collaboration with Per Svenningsson, MD, PhD, who is serving as the study's Lead Principal Investigator.

All amounts are expressed in thousands of U.S. dollars unless otherwise stated.

Currency rate fluctuations

Our operating currency is Canadian dollars, while our reporting currency is U.S. dollars. Accordingly, our results of operations and balance sheet position have been affected by currency rate fluctuations. In summary, our financial statements for the three-month period ended March 31, 2024 report an accumulated other comprehensive loss mainly due to foreign currency translation adjustments of $2,145 primarily due to the fluctuations in the rates used to prepare our financial statements, $308 of which positively impacted our comprehensive loss for the three-month period ended March 31, 2024. The following Management Discussion and Analysis takes this into consideration whenever material.

Reconciliation of Comprehensive Loss to Adjusted Earnings (Loss) before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA (Loss))

Adjusted EBITDA is a non-US GAAP financial measure. A reconciliation of the Adjusted EBITDA is presented in the table below. The Company uses adjusted financial measures to assess its operating performance. Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than US-GAAP do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. The Company uses Adjusted EBITDA to measure its performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends in our operating performance, and because the Company believes it provides meaningful information on the Company's financial condition and operating results.

IntelGenx obtains its Adjusted EBITDA measurement by adding / (deducting) to comprehensive loss, finance income and costs, depreciation and amortization, income taxes and foreign currency translation adjustment incurred during the period. IntelGenx also excludes the effects of certain non-monetary transactions recorded, such as share-based compensation, for its Adjusted EBITDA calculation. The Company believes it is useful to exclude these items as they are either non-cash expenses, items that cannot be influenced by management in the short term, or items that do not impact core operating performance. Excluding these items does not imply they are necessarily nonrecurring. Share-based compensation costs are a component of employee and consultant's remuneration and can vary significantly with changes in the market price of the Company's shares. Foreign currency translation adjustments are a component of other comprehensive income and can vary significantly with currency fluctuations from one period to another. In addition, other items that do not impact core operating performance of the Company may vary significantly from one period to another. As such, Adjusted EBITDA provides improved continuity with respect to the comparison of the Company's operating results over a period of time. Our method for calculating Adjusted EBITDA may differ from that used by other corporations.

Reconciliation of Non-US-GAAP Financial Information

	Three-month period
	ended March 31,

	2024		2023
	$		$
Comprehensive loss	(3,719	)	(2,920	)
Add (deduct):
Depreciation	202		192
Finance costs	792		319
Finance income	-		(14	)
Share-based compensation	300		11
Other comprehensive income	(308	)	(4	)

Adjusted EBITDA (Loss)	(2,733	)	(2,416	)

Adjusted Earnings (Loss) before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA Loss)

Adjusted EBITDA (Loss) increased by $317 for the three-month period ended March 31, 2024 to ($2,733) compared to ($2,416) for the three-month period ended March 31, 2023. The increase in Adjusted EBITDA (Loss) of $317 for the three-month period ended March 31, 2024 is mainly attributable to an increase in SG&A expenses of $400 before consideration of stock-based compensation, offset by a decrease in R&D expenses of $57 before consideration of stock-based compensation, a decrease in manufacturing expenses of $14 before consideration of stock-based compensation, and an increase in revenues of $12.

Results of operations for the three-month period ended March 31, 2024 compared with the three-month period ended March 31, 2023.

	Three-month period
	ended March 31,
	2024		2023
	$		$
Revenue	174		162

Research and development Expenses	789		822
Manufacturing Expenses	484		472
Selling, General and Administrative Expenses	1,934		1,295
Depreciation of tangible assets	202		192

Operating loss	(3,235	)	(2,619	)
Net loss	(4,027	)	(2,924	)
Comprehensive loss	(3,719	)	(2,920	)

Revenue

Total revenues for the three-month period ended March 31, 2024 amounted to $174, representing an increase of $12 or 7% compared to $162 for the three-month period ended March 31, 2023. The increase for the three-month period ended March 31, 2024 compared to the last year's corresponding period is attributable to increases in R&D revenues of $7 and Royalties on Product Sales of $5.

Research and development ("R&D") expenses

R&D expenses for the three-month period ended March 31, 2024 amounted to $789, representing a decrease of $33 or 4%, compared to $822 for the three-month period ended March 31, 2023.

The decrease in R&D expenses for the three-month period ended March 31, 2024 is attributable to decreases in the allocation of the 20% credit of $33 as per the strategic development agreement with atai, consulting fees of $26, patent expenses of $16, and lab supplies of $8, offset by increases in study costs of $30 and salary expenses of $20.

In the three-month period ended March 31, 2024 we recorded estimated Research and Development Tax Credits of $37, consistent with $37 that was recorded in the same period of the previous year.

Manufacturing expenses

Manufacturing expenses for the three-month period ended March 31, 2024 amounted to $484, representing an increase of $12 or 3%, compared to $472 for the three-month period ended March 31, 2023.

The increase in Manufacturing expenses for the three-month period ended March 31, 2024 is attributable to increases in salary expenses of $89 due to hiring and supplies and consumables of $8, offset by decreases in storage fees of $42, quality expenses of $22, consulting fees of $12, and repairs and maintenance of $9.

Selling, general and administrative ("SG&A") expenses

SG&A expenses for the three-month period ended March 31, 2024 amounted to $1,934, representing an increase of $639 or 49%, compared to $1,295 for the three-month period ended March 31, 2023.

The increase in SG&A expenses for the three-month period ended March 31, 2024 is attributable to the variation of the foreign exchange due to the depreciation of the CA dollar vs US currency in the amount of $401, increases in salaries and compensation expenses of $266 (mainly due to the issuance and revaluation of DSUs in the quarter and the grant of RSUs), consulting fees of $33, investor relations expenses of $14, and leasehold expenses of $6, offset by decreases in professional fees of $45, insurance expense of $24, and general office expenses of $12.

Depreciation of tangible assets

In the three-month period ended March 31, 2024 we recorded an expense of $202 for the depreciation of tangible assets, compared with an expense of $192 for the same period of the previous year.

Share-based compensation expense, warrants and stock-based payments

Share-based payments expense for the three-month period ended March 31, 2024 amounted to $300 compared to $11 for the three-month period ended March 31, 2023.

We expensed approximately $299 in the three-month period ended March 31, 2024 for options/PRSUs and RSUs granted to our employees in 2022, 2023 and 2024 under the 2022 Stock Option Plan and $1 for options granted to a consultant in 2024, compared with $8 and $3, respectively that was expensed in the same period of the previous year.

There remains approximately $514 in stock-based compensation to be expensed in fiscal 2024 through 2027 of which $12 relates to the issuance of options to a consultant during 2024. We anticipate the issuance of additional options and warrants in the future, which will continue to result in stock-based compensation expense

Key items from the balance sheet

		March 31, 2024		December 31, 2023		Increase/ (Decrease)			Percentage Increase/ (Decrease)
Current assets	$	2,077	$	3,441	$	(1,364	)	$	(40)%

Leasehold improvements and equipment, net		3,682		3,958		(276	)		(7%)

Security deposits		244		250		(6	)		(2%)

Operating lease right-of-use asset		545		633		(88	)		(14%)

Current liabilities (excluding convertible notes and loan payable)		6,282		5,866		416			7%

Loan payable		8,319		7,401		918			12%

Convertible notes		7,123		6,995		128			2%

Operating lease liability		170		230		(60	)		(26%)

Finance lease liability		20		37		(17	)		(46%)

Capital Stock		1		1		0			0%

Additional paid-in-capital		69,262		68,662		600			1%

Going concern

The Company has financed its operations to date primarily through public offerings of its common stock, proceeds from issuance of convertible notes and debentures, bank loans, royalty, up-front and milestone payments, license fees, proceeds from exercise of warrants and options, and research and development revenues. The Company has devoted substantially all of its resources to its drug development efforts, conducting clinical trials to further advance the product pipeline, the expansion of its facilities, protecting its intellectual property and general and administrative functions relating to these operations. The future success of the Company is dependent on its ability to develop its product pipeline and ultimately upon its ability to attain profitable operations. As of March 31, 2024, the Company had cash totaling approximately $772. The Company does not have sufficient existing cash to support operations for the next year following the issuance of these financial statements. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Therefore, management plans to explore any available strategic alternatives.

Current assets

Current assets totaled $2,077 as at March 31, 2024 compared with $3,441 as at December 31, 2023. The decrease of $1,364 is mainly attributable to a decrease in cash of $1,510, offset by increases in prepaid expenses of $16, investment tax credits receivable of $33, and inventory of $102.

Cash

Cash totaled $772 as at March 31, 2024 representing a decrease of $1,510 compared with the balance of $2,282 as at December 31, 2023. The decrease in cash on hand relates to net cash used in operating activities of $2,856, offset by net cash provided by financing activities of $943, and a positive foreign exchange effect of $403.

Accounts receivable

Accounts receivable totaled $618 as at March 31, 2024 representing a decrease of $4 compared with the balance of $622 as at December 31, 2023. The decrease is related to the collection of receivables offset by the invoicing of revenues incurred in the three-month period ended March 31, 2024.

Prepaid expenses

As at March 31, 2024 prepaid expenses totaled $239 compared with $223 as of December 31, 2023. The increase may be explained by advance payments made in January 2024.

Investment tax credits receivable

R&D investment tax credits receivable totaled approximately $201 as at March 31, 2024 compared with $168 as at December 31, 2023. The increase is attributable to the accrual estimated and recorded for the first three months of 2024.

Leasehold improvements and equipment

As at March 31, 2024, the net book value of leasehold improvements and equipment amounted to $3,682, compared to $3,958 at December 31, 2023. In the three-month period ended March 31, 2024 additions to assets totaled $Nil, and depreciation expense amounted to $202, offset by the variation of foreign exchange fluctuation.

Security deposit

A security deposit in the amount of CA$300 ($221) in respect of an agreement to lease approximately 17,000 square feet in a property located at 6420 Abrams, St-Laurent, Quebec, Canada was recorded as at March 31, 2024. Security deposits in the amount of CA$26 ($19) for utilities and CA$5 ($4) for Cannabis license were also recorded as at March 31, 2024. Security deposit in the amount of CA$100 ($74) for Company credit cards was also recorded as at March 31, 2024 but classified as short-term.

Accounts payable and accrued liabilities

Accounts payable and accrued liabilities totaled $3,023 as at March 31, 2024 compared with $2,661 as at December 31, 2023. The increase is attributable to an increase in trade payables for R&D and Manufacturing costs incurred.

Accrued interest expense

Accrued interest expense totaled $1,426 as at March 31, 2024 compared with $1,249 as at December 31, 2023. The increase is attributable to the fact that the interest expense has not been paid.

Term loan

Term loan totaled $500 as at March 31, 2024 and as at December 31, 2023. Atai has granted to the Company a secured term loan for $500, bearing interest at 14%. Principal of and interest on this Term Loan from time to time outstanding shall be due and payable from thirty five percent (35%) of the proceeds of each closing of equity financing until the principal balance and any outstanding balance is paid in full. Regardless of whether any closing of equity financing occurs, the outstanding and remaining principal balance and interest on this term loan shall be due and payable by December 31, 2024. The interest for the three-month period ended March 31, 2024 amounts to $18 and is recorded in financing and interest expense (2023 - $Nil).

Loan payable

Loan payable totaled $8,319 as at March 31, 2024 as compared to $7,401 as at December 31, 2023. As at March 31, 2024, loan payable in the amount of $7,649 (December 31, 2023: $Nil) were classified as short-term.

atai has granted to the Company a secured loan in the amount of $9,500, bearing interest at 8%. The loan is guaranteed by the Company and secured by all present and future movable property, rights and assets of the Company, excluding any intellectual property or technology controlled or owned by the Company. The loan is convertible into shares of common stock of the Company. $8,500 of the loan will mature on January 5, 2025, and $1,000 will mature on February 1, 2026. The interest for the three-month period ended March 31, 2024 amounts to $177 and is recorded in financing and interest expense ($164 in 2023). The accretion expense for the three-month period ended March 31, 2024 amounts to $253 (2023: $Nil).

Convertible notes

Convertible notes totaled $7,123 as at March 31, 2024 as compared to $6,995 as at December 31, 2023. The convertible notes have been recorded as a liability. As at March 31, 2024, convertible notes in the amount of $2,585 (December 31, 2023: $2,557) were classified as short-term. The accretion expense for the period ended March 31, 2024 amounts to $128 ($48 in 2023). The interest on the convertible notes as at March 31, 2024 amounts to $204 ($97 in 2023) and is recorded in Financing and interest expense.

Shareholders' deficit

As at March 31, 2024, we had accumulated a deficit of $82,484 compared with an accumulated deficit of $78,457 as at December 31, 2023. Total assets amounted to $6,548 and shareholders' deficit totaled $15,366 as at March 31, 2024, compared with total assets and shareholders' deficit of $8,282 and $12,247 respectively, as at December 31, 2023.

Capital stock

As at March 31, 2024 capital stock amounted to $1.746 (December 31, 2023: $1.746). Capital stock is disclosed at its par value with the excess of proceeds shown in Additional Paid-in-Capital.

Additional paid-in-capital

Additional paid-in capital totaled $69,262 as at March 31, 2024, as compared to $68,662 as at December 31, 2023. Additional paid in capital increased by $600 from which $300 was the value of the warrants granted to atai in connection with the Loan Agreement and $300 was from stock based compensation attributable to the amortization of stock options granted to employees.

Taxation

As at December 31, 2023, the date of our latest annual tax return, we had Canadian and provincial net operating losses of approximately $52,703 (December 31, 2022: $45,041) and $63,394 (December 31, 2022: $52,004) respectively, which may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2026 and 2043. A portion of the net operating losses may expire before they can be utilized.

As at December 31, 2023, the Company had non-refundable tax credits of $3,391 thousand (2022: $3,004 thousand) of which $8 thousand is expiring in 2026, $10 thousand is expiring in 2027, $170 thousand is expiring in 2028, $149 thousand is expiring in 2029, $127 thousand is expiring in 2030, $136 thousand is expiring in 2031, $170 thousand is expiring in 2032, $113 thousand is expiring in 2033, $86 thousand expiring in 2034, $101 thousand is expiring in 2035, $139 thousand expiring in 2036, $265 thousand is expiring in 2037, $572 thousand expiring in 2038, $346 thousand expiring in 2039, $226 thousand expiring in 2040, $231 thousand expiring in 2041, $270 thousand expiring in 2042, and $272 thousand expiring in 2043, and undeducted research and development expenses of $19,142 thousand (2022: $17,031 thousand) with no expiration date.

The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for.

Key items from the statement of cash flows

		March 31, 2024			March 31, 2023			Increase/ (Decrease)		Percentage Increase/ (Decrease)

Operating Activities	$	(2,856	)	$	(2,262	)	$	(594	)	26%
Financing Activities		943			3,648			(2,705	)	(74%)
Investing Activities		-			(74	)		(74	)	(100%)
Cash - end of period		772			2,520			(1,748	)	(69%)

Statement of cash flows

Net cash used in operating activities was $2,856 for the three-month period ended March 31, 2024, compared to $2,262 for the three-month period ended March 31, 2023. For the three-month period ended March 31, 2024, net cash used by operating activities consisted of a net loss of $4,027 (2023: $2,924) before depreciation, accretion expense, stock-based compensation, DSU expense and lease non-cash expense in the amount of $1,125 (2023: $396) and an increase in non-cash operating elements of working capital of $46 (2023: $266).

The net cash provided by financing activities was $943 for the three-month period ended March 31, 2024, compared to $3,648 for the same period of 2023. For the three-month period ended March 31, 2024, an amount of $1,000 derives from issuance of a convertible loan, offset by transaction costs of convertible loan of $35 and finance lease payments for an amount of $22. For the three-month period ended March 31, 2023, an amount of $3,000 derives from the issuance of a loan and an amount of $697 derives from net proceeds from convertible notes, offset by transaction costs of convertible notes of $40 and finance lease payments of $9.

Net cash used in investing activities amounted to $Nil for the three-month period ended March 31, 2024, compared to net cash used in investing activities of $74 for the three-month period ended March 31, 2023. The net cash used in investing activities for the three-month period ended March 31, 2023 relates to the purchase of fixed assets of $74.

The balance of cash as at March 31, 2024 amounted to $772, compared to $2,520 as at March 31, 2023.

Off-balance sheet arrangements

We have no off-balance sheet arrangements.

Item 3. Controls and Procedures.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based upon that evaluation, our chief executive officer and principal financial officer concluded that our disclosure controls and procedures are effective to cause the material information required to be disclosed by us in the reports that we file or submit under the Exchange Act to be recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. There have been no significant changes in our internal controls or in other factors which could significantly affect internal controls subsequent to the date we carried out our evaluation.

PART II

Item 1. Legal Proceedings

This Item is not applicable

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

This Item is not applicable.

Item 3. Defaults Upon Senior Securities

This Item is not applicable.

Item 4. (Reserved)

Item 5. Other Information

This Item is not applicable.

Item 6. Exhibits

Exhibit 31.1	Certification of C.E.O. Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 31.2	Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.1	Certification of C.E.O. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.2	Certification of Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS	Inline XBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document

101.SCH	Inline XBRL Taxonomy Extension Schema Document

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document

104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INTELGENX TECHNOLOGIES CORP.

Date: May 15, 2024		By: /s/ Dwight Gorham
		Dwight Gorham
		Chief Executive Officer

Date: May 15, 2024		By: /s/ Andre Godin
		Andre Godin
		Principal Accounting Officer

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

March 31,
2024

December 31,
2023

Authorized -

580,000,000 common shares of $0.00001 par value

20,000,000 preferred shares of $0.00001 par value

174,658,096 (December 31, 2023: 174,658,096) common shares